1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 11 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2006The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAILButler, L.; Liapis, V.; Bouralexis, S.; Welldon, K.; Hay, S.; Thai, L.; Labrinidis, A.; Tilley, W.; Findlay, D.; Evdokiou, A.
2004Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicinBouralexis, S.; Clayer, M.; Atkins, G.; Labrinidis, A.; Hay, S.; Graves, S.; Findlay, D.; Evdokiou, A.
2003Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapyBouralexis, S.; Findlay, D.; Atkins, G.; Labrinidis, A.; Hay, S.; Evdokiou, A.
2011Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivoZinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Findlay, D.; Zannettino, A.; Evdokiou, A.
2010Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat modelLabrinidis, A.; Hay, S.; Liapis, V.; Findlay, D.; Evdokiou, A.
2002Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosisAtkins, G.; Bouralexis, S.; Evdokiou, A.; Hay, S.; Labrinidis, A.; Zannettino, A.; Haynes, D.; Findlay, D.
2003Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikisEvdokiou, A.; Labrinidis, A.; Bouralexis, S.; Hay, S.; Findlay, D.
2008Does Apo2LTRAIL play any physiologic role in osteoclastogenesis?Labrinidis, A.; Liapis, V.; Thai, L.; Atkins, G.; Vincent, C.; Hay, S.; Sims, N.; Zannettino, A.; Findlay, D.; Evdokiou, A.
2009Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancerZinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Zannettino, A.; Findlay, D.; Evdokiou, A.
2009Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myelomaLabrinidis, A.; Diamond, P.; Martin, S.; Hay, S.; Liapis, V.; Zinonos, I.; Sims, N.; Atkins, G.; Vincent, C.; Ponomarev, V.; Findlay, D.; Zannettino, A.; Evdokiou, A.

Discover